Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis
Masaya Higuchi* and Masahiro Fujii

Address: Division of Virology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Niigata 951-8510, Japan
Email: Masaya Higuchi* - mhiguchi@med.niigata-u.ac.jp; Masahiro Fujii - fujimas@med.niigata-u.ac.jp
* Corresponding author

Abstract
While the human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia/lymphoma (ATL), to date, its close relative HTLV-2 is not associated with ATL or other types of malignancies. Accumulating evidence shows that HTLV-1 Tax1 and HTLV-2 Tax2 have many shared activities, but the two proteins have a limited number of significantly distinct activities, and these distinctions appear to play key roles in HTLV-1 specific pathogenesis. In this review, we summarize the functions of Tax1 associated with cell survival, cell proliferation, persistent infection as well as pathogenesis. We emphasize special attention to distinctions between Tax1 and Tax2.

Background
Adult T-cell leukemia/lymphoma (ATL) is an aggressive form of leukemia/lymphoma characterized by the malignant proliferation of CD4 T cells infected with human T-cell leukemia virus type 1 (HTLV-1) [1-4]. HTLV-1 infection also causes a neurodegenerative disease termed HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [5,6]. HTLV-1 belongs to the delta-retrovirus family, and it infects currently 10-20 million people in the world, especially in southwestern Japan, Africa, the Caribbean Islands and South America [7]. HTLV-1 transmission mainly occurs from mother to child through breast milk [8]. After the transmission and infection, HTLV-1 immortalizes the infected CD4 T-cells; and this immortalization establishes a life-long persistent infection in a host [9,10]. The immortalization of infected T-cells is likely to be dependent on cytokines [11] including interleukin (IL)-2, and perhaps also occurs in cytokine-independent (or less-dependent) ways as discussed later. Indeed, HTLV-1 transforms primary human CD4 T-cells in an IL-2-dependent manner in vitro. This transformation event of infected T-cells alone is, however, not sufficient for ATL development, since only a fraction of HTLV-1 infected individuals (approximately 5%) suffer ATL after a long latency period (60 years on average). Thus, both multiple genetic and epigenetic changes [12] in infected T-cells and the deterioration of host immune system are thought to be prerequisites for ATL development.

Intriguingly, a closely related delta-retrovirus, human T-cell leukemia virus type 2 (HTLV-2), does not cause any leukemia or lymphoma in infected people in spite of its ability to immortalize in vitro human T-cells in an IL-2-dependent manner as effectively as HTLV-1 [13]. Moreover, the association of HTLV-2 infection with HAM/TSP is quite rare. Thus, HTLV-2 should be regarded as defective in promoting certain steps of leukemogenesis and neurologic disease development, and this virus may be a useful comparative tool for understanding the pathogenic activities of HTLV-1. In addition, HTLV-3 and HTLV-4 have recently been identified from bushman hunters in central...
In addition to structure genes, *gag*, *pol*, and *env*, HTLV-1 encodes several non-structural genes including p12, p13, p30, Rex, and Tax (Figure 1) [17]. Among them, HTLV-1 Tax (Tax1) plays a central role in the immortalization of infected T-cells and the persistence of infection in a host. Tax1 immortalizes primary human T-cells in an IL-2 dependent manner, and transforms a T cell line CTLL-2 from IL-2 dependent growth into IL-2-independent growth [18-20]. In addition, Tax1 induces anchorage independent growth of a Rat-1 fibroblast cell line, and such cells can develop tumors in nude mice [21]. These results suggest that Tax1 has both immortalizing and oncogenic potentials.

Tax1 was originally identified as a transcriptional activator that interacts with a triuplicated Tax-responsive enhancer in the 5′ long terminal repeat (LTR) of the HTLV-1 genome [22,23]. In addition, through interacting with a number of cellular proteins, Tax1 functions in the survival of HTLV-1-infected T-cells, in cell cycle progression, cell growth, and in induced genomic instability [23-25]. All these Tax1 functions are thought to work cooperatively to transform HTLV-1 infected T-cells and have pivotal roles in the development of HTLV-1 associated diseases. Among them, Tax-induced genomic instability is undoubtedly involved in ATL development, but we will not discuss this topic because it has been reviewed well elsewhere [26-28]. Here, we will focus on the functions of Tax1 in cell survival, proliferation, and pathogenesis, with an emphasis on distinctions between HTLV-1 and HTLV-2 Tax proteins.

**Activation of the NF-κB pathway**

The NF-κB family of transcription factors, including RelA, c-Rel, RelB, NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and its precursor p100), plays a central role in immune functions, such as innate and adaptive responses to pathogens, survival of lymphocytes, and lymphoid tissue development [29]. On the other hand, aberrant NF-κB activation is implicated in the genesis of many types of cancer, especially hematologic malignancies such as leukemia, lymphoma, and myeloma [30]. There are two NF-κB-signaling pathways that regulate overlapping, but distinct sets of cellular genes; and these two pathways are called the canonical and the noncanonical NF-κB pathways. Inflammatory cytokines, genotoxic stress, antigens, and toll like receptor (TLR) stimulation activate the canonical pathway, whereas a subset of TNF family members, such as CD40L, lymphotoxin-β, BAFF, RANKL, and TWEAK activate the noncanonical pathway. While the activation of the canonical pathway results in the degradation of its inhibitor IkB and the translocation of the p50/RelA complex into the nucleus, the activation of the noncanonical pathway results in the processing of p100/RelB into p52/RelB and the translocation of the latter into the nucleus.

NF-κB activity is tightly controlled in normal T cells, and it is transiently activated in certain circumstances such as during immune stimulation. By contrast, NF-κB is constitutively active in HTLV-1-infected T cells [31-34]. This constitutive NF-κB activation is mediated by Tax, and the activity is essential for T cell transformation by HTLV-1 and HTLV-2. For instance, HTLV-1 and HTLV-2 carrying mutant tax1 and tax2 genes defective for NF-κB activation, can not immortalize primary human T cells [35,36] (however, in some cases of Tax over expression, NF-κB activity is not needed to immortalize primary human T cells [37]). In addition, Tax1 NF-κB mutants cannot transform CTLL-2 and Rat-1 cells, consistent with the importance of NF-κB activation for Tax1-induced cell growth promotion [20,38,39].

**Mechanism of NF-κB activation by Tax**

Both Tax1 and Tax2 activate the canonical NF-κB pathway through interacting with multiple NF-κB regulators. While the full scheme of canonical NF-κB activation by Tax has not been elucidated yet, the activation of the IKK complex by Tax through binding with its scaffold subunit IKKγ (NEMO) is a central event. The above conclusion was established based on the observation that the loss of NEMO completely abrogates the activation of NF-κB by Tax1 [40,41]. A MAP3K, TAK1, stimulates IKK activity upon various stimuli such as TLR, IL-1, and anti-CD3
stimulation [42]. Tax1, through interacting with TAK1, increases TAK1 kinase activity [43]. Thus, Tax1 functions as an adaptor, mediating the TAK1-IKK interaction through binding to both molecules.

Tax1 undergoes several posttranslational modifications, including phosphorylation, acetylation, sumoylation, and ubiquitination [44-50]. Among these, Tax1 ubiquitination is crucial for its binding to NEMO and for the subsequent NF-κB activation [48]. Tax1 polyubiquitination is predominantly composed of K63-linked chains, and such ubiquitination is dependent on the E2 ubiquitin conjugating enzyme, Ubc13 [48]. In addition, another Tax1 binding protein TAX1BP1 forms a ternary complex with the E3 ubiquitin ligase Itch and the ubiquitin-editing enzyme A20. The TAX1BP1-A20 deubiquitinase complex is a negative regulator of NF-κB activity induced by inflammatory cytokines; Tax1 can disrupt this inhibitory complex to thereby trigger constitutive NF-κB activation in HTLV-1-infected cells [51,52]. Recently, it was found that NEMO-Related Protein (NRP/Optineurin) binds to both Tax1 and TAX1BP1; this newly-described interaction can positively modulate Tax1 ubiquitination and NF-κB activation [53].

**Tax1 specific activation of NF-κB**

In addition to the canonical NF-κB pathway, Tax1 activates the noncanonical NF-κB pathway [54]. Tax1 simultaneously binds to the IKK complex and NF-κB2/p100, leading to IKKα mediated p100 phosphorylation and subsequent p100 processing into p52 [54]. Interestingly, HTLV-2 Tax2 cannot induce p100 processing into p52 when transiently expressed in the Jurkat T-cell line, although Tax2 can activate the canonical NF-κB pathway to a level comparable to Tax1 [55]. The major defect of Tax2 in p100 processing is an inability of Tax2 to interact with p100 [55]. The Tax1 region encompassing amino acids 225-232, overlapping with the leucine zipper like region (LZR), is responsible for Tax1-mediated p100 processing and p52 nuclear translocation (Figure 2) [56]. Since Tax1 LZR is not required for interaction with p100, Tax1 interaction with IKK complex and p100 is not sufficient for p100 processing. Thus, an as-yet-unidentified molecule which associates with the Tax1 LZR might be involved in the activation of the noncanonical NF-κB pathway.

The transforming activity of Tax1 towards CTLL-2 is much higher than that of Tax2, and such increased activity is partly mediated through Tax1-specific activation of the noncanonical NF-κB pathway [55-58]. For instance, the exogenous expression of an activator of the noncanonical pathway, a constitutively active NF-κB inducing kinase (NIK), restores the transforming activity of Tax2 to a level equivalent to that of Tax1 [55]. Interestingly, the requirement of NF-κB2 activation in Tax1 transformation appears to be T-cell specific, since the NF-κB2 activation by Tax1 is not needed in the transformation of Rat-1 [59]. Given the fact that aberrant activation of the noncanonical NF-κB pathway is associated with the development of mature T-cell leukemia and lymphoma [60], these results suggest that the activation of the noncanonical NF-κB pathway by Tax1 plays a role in HTLV-1 specific pathogenesis.

**NF-κB activation in T-cell transformation**

Continued cell cycle progression and resistance to apoptosis are two fundamental functions associated with the transformation of HTLV-1 infected T cells. NF-κB activation by Tax1 is critically involved in both functions. When expressed in G1- arrested primary human T cells, Tax1 induces cell cycle progression from the G1 to S phase through activation of E2F transcription factors [61]. The ability of Tax1 to promote cell-cycle progression is at least partially mediated through the induction of cyclin D2 and Cdk6 via the NF-κB pathway [62]. The activation of both the canonical and noncanonical NF-κB pathways by Tax1 is involved in this process, since knockdown of either RelA or NF-κB2/p100 by short hairpin RNA reduces Tax1-induced cell-cycle progression [62]. It is noteworthy that in addition to this NF-κB dependent function, Tax1 activates Cdk4/6 through direct interaction with Cdk4, Cdk6, and Cdk inhibitors such as p16INK4A and p15INK4B [63-
beneficial for the survival and proliferation of HTLV-1 infected cells in vivo through regulating T-cell functions such as cell survival, cell motility, adhesion, and tissue distribution. For instance, OX40 and 4-1BB, by inducing a cell to cell interaction, could further augment NF-kB activity, making a positive feedback loop, which would be important for the maintenance of NF-kB activity in HTLV-1-infected cells that express a low level of Tax1 in vivo [99].

**PDZ domain containing proteins**

PDZ (PSD-95/Discs Large/ZO-1) domain containing proteins bind to the PDZ domain binding motif (PBM) which is typically present at the carboxyl-terminus of target proteins [100]. One major structural difference between Tax1 and Tax2 is the presence of a PBM at the C-terminus of Tax1, but not Tax2 (Figure 2). It has been shown that deletion of the PBM from HTLV-1 (HTLV-1/ΔPBM) abrogates the persistent HTLV-1 infection in rabbits, whereas the PBM is dispensable for IL-2-dependent immortalization of primary human T-cells [101]. How does the Tax1 PBM play a role in persistent HTLV-1 infection in vivo without affecting the IL-2-dependent immortalization of primary T-cells? Interestingly, the deletion of PBM prominently reduces IL-2-independent growth of CTLL-2 cells induced by Tax1 [57]. Taken into account that the steady state level of IL-2 in vivo is generally too low to support IL-2-induced T-cell proliferation, the reduced requirement of IL-2 induced by Tax1 through PBM may explain the selectively defective function of HTLV-1/ΔPBM in vivo.

It is unclear how the Tax1 PBM contributes to inducing IL-2-independent growth of T-cells. The addition of Tax1 PBM to the C-terminus of Tax2 in the context of HTLV-2 significantly increases the proliferation of primary human T-cells infected with the virus in vitro [101]. Thus, Tax1 PBM may engage in the cell growth promoting activity of Tax1. In addition, it should be noted that the Tax1 PBM has an activity to induce micronuclei in Tax1 expressing cells [101-103]. Thus, the Tax1 PBM may have an activity associated with the genomic instability observed in HTLV-1 infected cells.

Similar to the pathogenesis differences between HTLV-1 versus HTLV-2, limited subtypes of human papilloma viruses (HPVs) such as HPV16 and 18 are associated with cervical cancers. Interestingly, the E6 oncoproteins from only high risk HPVs, but not low-risk HPVs have a PBM [100]. A similar pattern of subtype specific oncogenesis is also observed for human adenovirus type 9. Intriguingly, the PMFs from the oncogenic HPV E6 and the adenovirus E4-ORF1 can efficiently substitute for the Tax1 PBM in transforming CTLL-2 cells (submitted for publication). Thus, the targeting of PDZ domain containing proteins is likely to contribute an important mechanism to cellular transformation and pathogenesis by tumorigenic viruses.
Tax1 has been reported to interact with several PDZ domain containing proteins including Dlg1, Scribble, MAGI-3, TIP-1, IL-16 precursor protein, and Erbin [59,104-111]. Below, we discuss the possible involvement of Dlg1 and Scribble in Tax1 function. These proteins are believed to play important roles in the regulation of cell polarity, proliferation, and apoptosis.

**Dlg1**

Dlg1 is a mammalian homologue of Drosophila disc-large (dlg) and a member of the membrane-associated guanylate kinase (MAGUK) family proteins [112]. Homozygous dlg mutations in Drosophila cause neoplastic overgrowth of imaginal disc epithelia and embryonic lethality, establishing dlg as a tumor suppressor gene in Drosophila. In mammalian epithelial cells, Dlg1 localizes at adherence junctions (AJ) and is involved in the establishment of AJ as well as tight junctions. Following T cell receptor (TCR) activation in T cells, Dlg1 is transiently translocated to the immune synapses where it functions as a scaffold coordinating the activities of signaling proteins such as Lck, Zap70, Vav, WASP, and p38 kinase [113-116]. T cells from Dlg1 knockout mice show a hyperproliferative response to TCR stimulation, although proximal TCR signaling events such as tyrosine phosphorylation of signaling molecules, calcium mobilization, and IL-2 production are indistinguishable from wild type T cells, indicating that Dlg1 functions as a negative regulator of T cell proliferation [117].

Consistent with its tumor suppressive activity, the overexpression ofDlg1 in NIH-3T3 cells induces cell cycle arrest in G1, and this arrest can be overcome by Tax1 in a PBM dependent manner, indicating that Tax1, through direct binding, interferes with the growth-suppressive activity of Dlg1 [106]. Although it has not been elucidated yet how Tax1 inactivates Dlg1 function, Tax1 induces the hyperphosphorylation of Dlg1 by an unknown mechanism, and alters its subcellular localization from the detergent soluble to the detergent insoluble fraction [59]. Unlike Tax1, E6 inactivates Dlg1 by ubiquitination mediated proteosomal degradation [118]. Consistent with the fact that Dlg1 deficiency in T cells augments cell proliferation, Dlg1 knockdown by short hairpin RNA in CTLL-2 cells augments Tax1 mediated transformation, although the knockdown alone cannot rescue the transforming activity of a Tax1 PBM mutant incapable of binding to Dlg1 [119]. These results suggest that the inactivation of Dlg1 is required for Tax1 mediated transformation of CTLL-2, but this is not sufficient, and other PDZ domain containing proteins are involved in the activity of PBM.

**Scribble**

Scribble is a member of the LAP (leucine rich and PDZ domain) family of proteins and functions as a cell polarity protein in cooperation with Dlg1 [112]. Like dlg, loss-of-function mutation of scrib in Drosophila results in aberrant proliferation and abnormal cell polarity/architecture of epithelial cells, indicating a role for Scribble as a tumor suppressor. In mammalian epithelial cells, Scribble and Dlg1 also form a scaffolding complex, regulating apical-basal polarity. In T cells, the Scribble complex regulates T cell polarity and morphology during migration and immunological synapse formation [115].

Tax1 binds to Scribble in a PBM dependent manner, although one report suggests there are both PBM-dependent and -independent modes of Tax1-Scribble binding [107,108]. Scribble is diffusely localized at the plasma membrane of HTLV-1-uninfected T-cell lines, whereas it colocalizes with Tax1 as small or large aggregates at the plasma membranes, suggesting that Tax1 induces aberrant clustering of Scribble, thereby altering its functions in HTLV-1-infected cells [107,108]. Although Scribble is targeted for ubiquitin mediated degradation by high-risk HPV E6, there seems to be no obvious degradation of Scribble in HTLV-1 transformed cells, suggesting that alteration of the subcellular localization of Scribble by Tax1 is the main mechanism to inactivate its function. Scribble over expression in Jurkat cells suppresses TCR-induced NFAT activity, and this suppression is relieved by Tax1 in a PBM dependent manner, indicating that Tax1 interferes with Scribble function although the significance of this finding in infected T-cells remains unclear [107].

While it is very likely that viral oncoproteins including Tax1 inactivate the tumor suppressive functions of PDZ domain proteins, it remains possible that they might positively utilize such PDZ proteins to transform cells. This idea was raised in order to explain the function of E4-ORF1, since the loss of Dlg1 apparently reduces the transforming activity of E4-ORF1 [120]. By analogy, Tax1 might take advantage of PDZ domain containing protein(s) to localize at certain cellular organelles, such as cell membranes, in order to activate signaling pathways important for cell growth and survival. Thus, the understanding of the whole picture of Tax1 PBM function in HTLV-1 mediated T-cell transformation is still incomplete, and further studies are needed.

**Activation of PI3K and Akt pathway**

PI3K and its downstream kinase Akt are activated in T cells by many cytokines including IL-2; this pathway provides cell survival and growth signals [121]. Activated PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate to produce phosphatidylinositol 3,4,5-trisphosphate (PIP3) which binds and activates Akt. Activated Akt in turn phosphorylates its downstream substrates which are involved in cell survival and cell growth. On the other hand, PIP3 phosphatases, such as phosphatase and tensin
homolog deleted on chromosome 10 (PTEN) and Src homology 2 domain containing inositol polyphosphate phosphatase-1 (SHIP-1), dephosphorylate PIP3 to down-regulate Akt activity.

In many cancers, the PI3K/Akt pathway is aberrantly activated by several means, including the gain of function mutation in PI3K and Akt, the loss of PTEN, and the constitutive activation of upstream signaling molecules such as the mutation of ras [122]. In both HTLV-1 transformed and ATL cells, the PI3K/Akt pathway is constitutively active [123,124]. LY294002 (an inhibitor of PI3K) or AKT inhibitor II induces cell cycle arrest at G1 phase in HTLV-1 transformed cells through p27/kip1 accumulation, and they subsequently induce caspase-9 dependent apoptosis [101]. These findings indicate that PI3K/Akt activation by Tax1 is critically involved in the growth of HTLV-1-infected T-cells [125].

Several distinct mechanisms for Tax1 to activate PI3K/Akt have been reported. Tax1 frees a catalytic p110α subunit of PI3K complex from an inhibitory subunit p85α through direct binding to p85α [124]. Tax1 also downregulates the expression of PTEN and SHIP-1 through RelA-mediated sequestration of the transcriptional coactivator p300 from the promoters of PTEN and SHIP-1 [126]. In addition, Tax1 through the CREB/ATF-1 pathway activates Akt in 293T cells, although in this setting the precise mechanism remains unclear [127].

The mammalian target of rapamycin (mTOR) is one of the crucial downstream targets of Akt which is used to promote cell survival and growth mainly through the stimulation of translational initiation [128]. Rapamycin, an inhibitor of mTOR kinase activity, inhibits the phosphorylation of p70S6 kinase and 4E-BP1, thereby inducing growth inhibition and G1 cell cycle arrest of HTLV-1 transformed cells. These findings are consistent with mTOR activation being important for Tax1 induced cell cycle progression [129]. In addition to mTOR, AP-1, NF-kB, β-catenin, and HIF-1 are activated by Tax1 through PI3K/Akt in HTLV-1-infected T-cells, and these factors also seem to be involved in HTLV-1 mediated T-cell transformation [124,125,127,130].

Paradoxical to the virus' transforming activity, Tax1 expression in or HTLV-1 infection of human cells (HeLa, SupT1 T-cell line) has been observed in some settings to induce cell cycle arrest at the G1 phase through the induction of p27/kip1 and p21/waf1 [131]. This is often associated with the premature activation of the anaphase-promoting complex (APC) [132]. This type of growth inhibition by Tax1 or HTLV-1 infection is abrogated by elevated Akt activity [133]. These results suggest that Akt activation by Tax1 in cells may not be sufficient to inactivate p27/kip1 and p21/waf1 functions, and that additional inactivation of p27/kip1 and p21/waf1 by genetic and/or epigenetic alterations could be essential for HTLV-1 to transform T-cells. It should be noted that 8 to 9 weeks after infection with HTLV-1, primary human T-cells can start to proliferate [101]; this lag time may be due to the interval of time needed to obtain genetic and/or epigenetic changes in order to escape cell cycle arrest induced by Tax1.

**Tax3 and Tax4**

Like HTLV-1 and HTLV-2, HTLV-3 and HTLV-4 encode Tax3 and Tax4, respectively. In their cognate viruses, Tax3 and Tax4 could play major roles in T-cell immortalization and persistent infection (Figure 2) [15,16]. Amino acid comparisons show that Tax3, but not Tax4, has a PBM at its C-terminus, and can bind to a PDZ domain derived from Dlg4 [15]. In addition, Tax3 and Tax4 show more homology to Tax2 than Tax1 in the LZR region which is important for the noncanonical activation of NF-κB. However, it has not been verified whether Tax3 and/or Tax4 activate the noncanonical NF-κB pathway. Therefore, the PBM and the LZR classify these four HTLVs into at least three distinct groups. Taken together, the PBM and LZR motifs could play significant roles in the respective life cycles of the HTLVs and contribute to their pathogenesis.

**HBZ**

Although the tax gene plays central roles in the immortalization and persistence of virus infected cells, its expression is inactivated in approximately 60% of in vivo ATL cases by mutation of the coding region and/or the transcriptional silencing through epigenetic mechanisms such as DNA methylation of the 5’ LTR [134-139]. These findings suggest that Tax1 is not needed in the maintenance of the leukemic stage in some ATL cases. The frequent inactivation of the tax gene was originally interpreted to imply the dispensability of any HTLV genes for the maintenance of the leukemic stage in certain ATL cases. This was a reasonable interpretation since the expression of viral genes other than tax was usually not detected in ATL cells. Recent studies, however, showed that the HTLV-1 basic leucine zipper factor (HBZ) encoded by the virus in an antisense orientation may play a critical role in the malignant proliferation of ATL cells (Figure 1) [140]. The expression of HBZ gene is detected in all ATL cases, and this is due to the usage of the promoter in the 3’ LTR of HTLV-1 gene which is not inactivated in the ATL cells [141,142]. Short hairpin RNA mediated knockdowns of HBZ expression in both ATL and HTLV-1 transformed cell lines reduce their proliferation [141,143]. Moreover, transgenic mice expressing HBZ under the control of the CD4 promoter/enhancer display increased numbers of CD4-positive T-cells in the spleen, and augmented prolif-
Cytokines are low amounts of IL-2 or similar T-cell growth-promoting activity. A model for HTLV-1-specific pathogenesis

Figure 3
A model for HTLV-1-specific pathogenesis. The amounts of IL-2 or similar T-cell growth-promoting cytokines are low in vivo. In such environment, HTLV-1 infected cells proliferate more efficiently than HTLV-2 infected cells, and have greater probability to acquire genetic and/or epigenetic mutations. In addition, increased proliferation of HTLV-1 infected T-cells would effectively deteriorate the host immune system. Once such mutated cells accumulate with a reduced host immune activity, HTLV-1-infected T-cells can grow monoclonally, resulting in ATL development. For HAM/TSP, an increase in HTLV-1-infected cells in vivo induces more immune response to HTLV-1, especially to Tax1, resulting in HAM/TSP development through an autoimmune mechanism.

...erylation of thymocytes after anti-CD3 stimulation [141]. Thus, these findings indicate that HBZ has a growth promoting activity, and could be involved in the malignant proliferation of ATL cells in vivo, although the precise molecular mechanism for these findings is still unclear. HTLV-2 also encodes a HBZ-like protein, designated as the antisense protein of HTLV-2 (APH-2) [144]. Interestingly, unlike HBZ, APH-2 does not have a leucine zipper motif which is essential for various HBZ functions. Thus, it is important to study whether the HTLV-2 APH-2 protein has a growth promoting activity in T-cells like HBZ in order to understand better how these two viruses show distinct pathogenicities.

Conclusion
This review article summarizes our current view pertaining to the molecular mechanism(s) of HTLV-1-mediated T-cell transformation and persistent infection. In our opinion, these mechanism(s) shed light on viral pathogenesis, and offer insights into differences in HTLV-1 Tax1 and HTLV-2 Tax2 function. Based on current information, we propose the following simplified model (Figure 3) which does not incorporate other potentially important factors such as oncogenic microRNAs [145-147]. HTLV-1-infected T-cells grow equivalently to HTLV-2-infected cells in environments with sufficient amount of IL-2 or other T-cell growth promoting cytokines in vivo, but HTLV-1 infected cells under conditions of low cytokines can grow much more efficiently than HTLV-2-infected cells. Such growth advantage of HTLV-1 infection would cause more expansion of infected cells in vivo, resulting in increased probability of acquiring genetic alterations, followed by clonal expansion of altered cells, and eventually leading to ATL development. It should be noted that high HTLV-1 proviral load (high numbers of infected cells) is a tightly-linked risk factor for the development of ATL. Such cytokine-independent (or less-dependent) growth properties of HTLV-1 infected T-cells are mediated by Tax1, possibly cooperatively with HBZ. To induce IL-2-independent growth of T-cells, Tax1 has two activities distinct from Tax2: the activation of the noncanonical NF-κB2 pathway and as-yet-uncharacterized signals through PDZ-domain-containing proteins. These two activities are already known to play crucial roles in hematopoietic malignancies including leukemia and lymphoma and carcinogenesis induced by high-risk HPV's. This model would also be applicable to the pathogenesis of HAM/TSP, since high proviral loads are also tightly-linked risk factors for HAM/TSP. In HAM/TSP, the increased expansion of HTLV-1 infected T-cells would further raise high immune response to the virus, especially to Tax1, resulting in the development of diseases possibly through already proposed autoimmune mechanism(s). Collectively, we believe that further comparisons of Tax functions from the four human HTLVs will promote greater understanding of viral pathogenesis. In addition, therapies targeted against functions specific to Tax1 could be promising for the treatment of HAM/TSP and certain ATL patients.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MH and MF cooperatively wrote and edited this review. Both authors read and approved the final manuscript.

Acknowledgements
We thank Kuan-Teh Jeang for editorial comments and editing the manuscript.

References
1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980, 77:6476-6480.
2. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I: Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981, 78:6476-6480.
3. Takatsuki K: Discovery of adult T-cell leukemia. Retrovirology 2005, 2:16.
4. Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7:270-280.
5. Osame M, Usuku K, Izumo S, Iijichi N, Amatani H, Igata A, Matsumoto M, Taya M: HTLV-I associated myelopathy, a new clinical entity. Lancet. 2001, 1:101-1032.
6. Bangham CR, Osame M: Cellular immune response to HTLV-I. Oncogene 2005, 24:6035-6046.
7. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24:6058-6068.
8. Kinoshita K, Amagasaki T, Hino S, Doi H, Yamanouchi K, Ban N, Momita S, Ikeda S, Kamihira S, Ichimura M, et al.: Milk-borne transmission of HTLV-I from carrier mothers to their children. Jpn J Cancer Res 1987, 78:674-680.
9. Miyoshi I, Kobonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraiishi Y, Nakata K, Hikuma Y: Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukemic T cells. Nature 1981, 294:770-771.
10. Yamamoto N, Okada M, Koyanagi Y, Kannagi M, Hikuma Y: Transforming human T-cell leukemia virus producer cell line. Science 1982, 217:733-739.
11. Teruya H, Tomita M, Senba M, Ishikawa C, Tamayose M, Miyazato A, Yara S, Tanaka Y, Iwakura Y, Fujita J, Mori N: Human T-cell leukemia virus type I infects human lung T-cell lines and induces expression of cytokines, chemokines and cell adhesion molecules. Retrovirology 2008, 5:86.
12. Bogenberger JM, Laybourn PJ: Human T Lymphotropic Virus Type I protein Tax reduces histone levels. Retrovirology 2008, 5:9.
13. Feuer G, Green PL: Comparative biology of human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II. Oncogene 2005, 24:5996-6004.
14. Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe SD, Wolitzky SJ, Pryor KN, Wolfe ND, Burke DS, Folks TM, Heneine W: The human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
15. Calattini S, Chevalier SA, Duprez R, Onofre P, Froment A, Gessain A, Momita S, Ikeda S, Kamihira S, Ichimura M, Tara M: Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005, 24:5988-5993.
16. Peruzzi M, Willems L: Mechanisms of HTLV-I persistence and transformation. Br J Cancer 2009, 101:1501-1508.
17. Vallabhapurapu S, Kirin M: Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733.
18. Mimura D, Oikawa K, Osakada M, Kato T, Kimura K, Takahashi A, Takahashi A: Activation of NF-kappaB by the human T-cell leukemia virus type I Tax retards the progression of cell cycle. J Virol 2000, 74:1650-1662.
19. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein modulates its activity. Oncogene 2004, 23:1064-1075.
20. Miki M, Kimura K, Osakada M, Kato T, Kimura K, Takahashi A, Takahashi A: Constitutive activation of NF-kappaB by the human T-cell leukemia virus type I Tax mutants expressed in a functional molecular clone. J Virol 1999, 73:4586-4587.
21. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
22. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
23. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
24. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
25. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
26. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
27. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
28. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
29. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
30. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
31. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
32. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
33. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
34. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
35. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
36. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
37. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
38. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
39. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
40. Pan C, Ooi C, Chang C, Sato T, Fujii M: Human T-cell leukemia virus type I Tax protein. Adv Immunol 1988, 4570-4575.
ylation and succinylation control critical cytoplasmic and nuclear steps of NF-kappaB activation. J Biol Chem 2007, 282:2758-2765.

59. Tsubata C, Higuchi M, Niinuma A, Ohashi M, Fukushi M, Oie M, Akiyama T, Uchida-Toita M, Yoshida M: Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-I through two distinct mechanisms. Mol Cell Biol 1999, 19:384-391.

60. Shoji T, Higuchi M, Kondo R, Takahashi M, Oie M, Tanaka Y, Aoyagi Y, Fujii M: Identification of a novel motif responsible for the distinctive transforming activity of human T-cell leukemia virus (HTLV) type 1 Tax protein from HTLV-2 Tax. Retrovirology 2009, 6:83.

61. Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, Cervelli S: Ubiquitination of HTLV-I Tax in response to DNA damage regulates nuclear complex formation and nuclear export. Retrovirology 2007, 4:95.

62. Iwanaga R, Iwasaki R, Kadowaki T, Tamura T, Marrott SJ: Ubiquitination of the HTLV-I Tax protein binding domain of the Bcl-xL expression is regulated by the NF-kappaB pathway. J Virol 2008, 82:11900-11907.

63. Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, Cervelli S: Ubiquitination of HTLV-I Tax in response to DNA damage regulates nuclear complex formation and nuclear export. Retrovirology 2007, 4:95.

64. Shoji T, Higuchi M, Niinuma A, Ohashi M, Fujii M: Activation of the cyclin D2 and cdk6 genes through selective NF-kappaB activation. J Biol Chem 2007, 282:2758-2765.

65. Tsubata C, Higuchi M, Niinuma A, Ohashi M, Fukushi M, Oie M, Akiyama T, Uchida-Toita M, Yoshida M: Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-I through two distinct mechanisms. Mol Cell Biol 1999, 19:384-391.

66. Krueger A, Fas SC, Giassi M, Bleumink M, Merling A, Stumpf C, Baumann S, Holtkotte D, Bosich V, Krammer PH, Li-Weber M: HTLV-I Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 2006, 107:6805-6815.

67. Suzuki T, Kitao S, Matsushima H, Yoshida M: HTLV-I Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. Embo J 1999, 18:1607-1614.

68. Low KG, Dorner LF, Fernando DB, Grossman J, Jeang KT, Comb PJ: Human T-cell leukemia virus type 1 Tax releases cell cycle arrest from p21-dependent growth inhibition by inducing cellular FLIP through activation of NF-kappaB. J Virol 2005, 79:1811-1820.

69. Balda MJ, Bohnlein E, Hoffmann JA, Bogerd HP, Dixon EP, Franza BR, Greene WC: Activation of the interleukin-2 receptor alpha gene: regulatory role for DNA-protein interactions flanking the beta enhancer. New Biol 1989, 1:83-92.

70. Ruben SM, Perkins A, Rosen CA: Activation of NF-kappa B by the HTLV-I trans-activator protein Tax requires an additional factor present in lymphoid cells. New Biol 1989, 1:275-284.

71. Chen J, Petrus M, Bryant BR, Phuc Nguyen V, Stamer M, Goldman CK, Bamford R, Morris JC, Janik JE, Waldmann TA: Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 2008, 111:5163-5172.

72. Waldele K, Silbermann K, Schneider G, Ruckes T, Cullen BR, Grassmann R: Requirement of the human T-cell leukemia virus (HTLV-I) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Virology 2004, 327:83-92.

73. Waldele K, Schneider G, Ruckes T, Cullen BR, Grassmann R: Interleukin-13 overexpression by tax transactivation: a potential autocrine stimulus in human T-cell leukemia virus-infected lymphocytes. J Virol 2004, 78:6081-6090.

74. Silbermann K, Schneider G, Grassmann R: Stimulation of interleukin-13 expression by human T-cell leukemia virus type 1 oncprotein Tax via a dually active promoter element confers resistance to NF-kappaB and NF. J Gen Virol 2008, 89:2788-2798.

75. Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA: Human T-cell lymphotropic virus type 1 oncprotein Tax activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci USA 1996, 93:2452-2457.

76. Mariner JM, Lantz V, Waldmann TA, Azimi N: Human T cell lymphotropic virus type 1 Tax activates IL-15R alpha gene expression through an NF-kappaB site. J Immunol 2001, 166:2602-2609.
83. Mizuguchi M, Asao H, Hara T, Higuchi M, Fujii M, Nakamura M: Transcriptional activation of the interleukin-21 gene and its receptor gene by human T-cell leukemia virus type 1 Tax in human T-cells. *J Biol Chem* 2009, 284:25501-25511.

84. Mori N, Mukaida N, Ballard DW, Matsushima K, Yamamoto N: Human T-cell leukemia virus type 1 Tax transactivates human interleukin 8 gene through acting concurrently on AP-1 and nuclear factor-kappaB-like sites. *Cancer Res* 1998, 58:3993-4000.

85. Mori N, Ueda A, Ikeda S, Yamasaki Y, Yamada Y, Tomonaga M, Morikawa S, Gelezunis R, Yoshimura T, Yamamoto N: Human T-cell leukemia virus type 1 tax activates transcription of the human monocyte chemotactant receptor-1 gene through two nuclear factor-kappaB sites. *Cancer Res* 2000, 60:4939-4945.

86. Mori N, Krensky AM, Oshikawa K, Tomita M, Matsuda T, Ohta T, Yamada Y, Tomonaga M, Ikeda S, Yamamoto N: Elevated expression of the CCL5 gene by human T-cell leukemia virus type 1. *Int J Cancer* 2004, 111:548-557.

87. Hieshima K, Nagakubo D, Nakayama T, Hirakawa AK, Jin Z, Yoshi O: Tax-inducible production of CC chemokine ligand 22 by human T-cell leukemia virus type 1 (HTLV-I)-infected T cells promotes preferential transmission of HTLV-I toCCR4-expressing CD4+ T cells. *J Immunol* 2008, 180:931-939.

88. Nagakubo D, Jin Z, Hieshima K, Nakayama T, Hirakawa AK, Tanaka Y, Hasegawa H, Hayashi T, Tsukasaki K, Yamada Y, Yoshi O: Expression of CCR9 in HTLV-I+ T cells and ATL cells expressing Tax. *Int J Cancer* 2007, 120:1591-1597.

89. Jin Z, Nagakubo D, Shirakawa AK, Nakayama T, Shigeta A, Hieshima K, Yamada Y, Yoshi O: CCR7 is inducible by HTLV-I Tax and promotes growth and survival of HTLV-I infected T cells. *Int J Cancer* 2009, 125:2229-2235.

90. Harhaj EW, Harhaj NS, Grant C, Mostoller K, Alefantis T, Sun SC, Inoue J, Yoshida M, Taniguchi T: HTLV-I and HTLV-II Tax: differences in induction of microRNAs in adult T-cell leukemia cells and microRNA-21 in T cells. *J Biol Chem* 2007, 282:33192-33194.

91. Higashimura N, Takahashi M, Higuchi M, Mori N, Fukushi M, Oie M, Coffey RJ, Yoshiura K, Tanaka Y, Uchiyama M, Hatanaka M, Fujii M: Human T-cell leukemia virus type 1 Tax promotes mislocalization of the tumor suppressor hScrib in T cells. *J Biol Chem* 2008, 283:14590-14598.

92. Mizuguchi M, Asao H, Hara T, Higuchi M, Fujii M, Nakamura M: Scaffold protein Dlgh1 coordinates alternative p38 MAPK and NFAT but not NF-kappaB transcription factors. *Oncogene* 2008, 27:10361-10372.

93. Majone F, Semmes OJ, Cantemir C, Turchetto L, Hjelle B, Jeang KT: HTLV-I and HTLV-II Tax: differences in induction of microRNAs in cells and transcriptional activation of viral LTRs. *Virology* 2009, 381:217-232.

94. Lee SS, Weiss RS, Javier RT: Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. *Proc Natl Acad Sci USA* 1997, 94:6670-6675.

95. Xie L, Yarunyanathan B, Higa A, Semmes OJ, Green PL: Tax binding motif of HTLV-I Tax promotes virus-mediated T-cell proliferation in vitro and persistence in vivo. *Blood* 2006, 107:1980-1988.

96. Thomas M, Narayan N, Pir D, Tomacch V, Massimi P, Naganaka K, Kranjec C, Gammon N, Banks L: Human papillomaviruses, cervical cancer and cell polarity. *Oncogene* 2008, 27:7018-7903.
119. Ishioka K, Higuchi M, Takahashi M, Yoshida S, Oie M, Tanaka Y, Takahashi S, Xie L, Green PL, Fujii M: Inactivation of tumor suppressor Dlg1 augments transformation of a T-cell line induced by human T-cell leukemia virus type I Tax protein. Retrovirology 2006, 3:71.

120. Frese KK, Latorre IJ, Chung SH, Caruana G, Bernstein A, Jones SN, Donehower LA, Justice MJ, Garner CC, Javier RT: Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor. EMBO J 2006, 25:1406-1417.

121. Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.

122. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.

123. Fukuda R, Hayashi A, Utsunomiya A, Nukada Y, Fukui R, Itoh K, Tezuka K, Ohashi K, Mizuno K, Sakamoto M, Hamanoue M, Tsuchi T: Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL). Proc Natl Acad Sci USA 2005, 102:15213-15218.

124. Peloponese JM Jr, Jeang KT: Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type I tax oncoprotein. J Biol Chem 2006, 281:8927-8936.

125. Jeong SJ, Dasgupta A, Jung KJ, Um JH, Burke A, Park HU, Brady JN: PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells. Virology 2008, 370:264-272.

126. Fukuda RI, Tsukiyama K, Suzuki K, Itoh K, Fujita J, Utsumi A, Tsuji T: Human T-cell leukemia virus type I tax down-regulates beta-catenin signaling. J Virol 2009, 83:2680-2689.

127. Tomita M, Kikuchi A, Aiyama T, Tanaka Y, Mori N: Human T-cell leukemia virus type I tax dysregulates beta-catenin signaling. J Virol 2006, 80:10497-10505.

128. Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.

129. Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuroyama Y, Adachi Y, Takeuchi T, Koefler HP, Taguchi H: Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 2007, 31:673-682.

130. Tomita M, Semenza GL, Michiels C, Matsuda T, Uchihara JN, Okuda A, Tanaka Y, Taira N, Ohshiro K, Mori N: Activation of hypoxia-inducible factor 1 in human T-cell leukemia virus type I-infected cell lines and primary adult T-cell leukemia cells. Biochem J 2007, 406:317-323.

131. Zhang L, Zhi H, Liu M, Kuo YL, Giam C: Induction of p21(CIP1/WAF1) expression by human T-lymphotropic virus type I Tax requires transcriptional activation and mRNA stabilization. Retrovirology 2009, 6:35.

132. Merling R, Chen C, Hong S, Zhang L, Liu M, Kuo YL, Giam C: HTLV-I Tax mutants that do not induce G1 arrest are disabled in activating the anaphase promoting complex. Retrovirology 2007, 4:35.

133. Liu M, Yang L, Zhang L, Liu B, Merling R, Xia Z, Giam C: Human T-cell leukemia virus type I infection leads to arrest in the G1 phase of the cell cycle. J Virol 2008, 82:8442-8455.

134. Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, Tanaka Y, Matsuoka M: Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer 2004, 109:559-567.

135. Furukawa Y, Kubota R, Tara M, Izuono S, Osame M: Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 2001, 97:987-993.

136. Tamiya M, Matsuoka M, Etoh K, Watanabe T, Kamihiira S, Yamaguchi K, Takatsuki K: Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1994, 83:3065-3073.

137. Miyazaki M, Yasunaga J, Taniguchi Y, Tamiya S, Nakahata T, Matsuoka M: Preferential Selection of Human T-Cell Leukemia Virus Type I Provirus Lacking the 5’ Long Terminal Repeat during Oncogenesis. J Virol 2007, 81:5714-5723.

138. Koika T, Hamano-Usmarty A, Ishida T, Okuyama A, Yamaguchi K, Kamihiira S, Watanabe T: 5’-long terminal repeat-selective Cpg methylation of latent human T-cell leukemia virus type I provirus in vitro and in vivo. J Virol 2002, 76:9389-9397.

139. Taniguchi Y, Nosaka K, Yasunaga J, Maeda M, Mueller N, Okaya M, Matsuoka M: Silencing of human T-cell leukemia virus type I gene expression by epigenetic mechanisms. Retrovirology 2005, 2:64.

140. Matsuoka M, Green PL: The HBZ gene, a key player in HTLV-I pathogenesis. Retrovirology 2009, 6:71.

141. Satou Y, Yasunaga J, Yoshida M, Matsuoka M: HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 2006, 103:720-725.

142. Usui T, Yagahira K, Tsukasaki K, Murata K, Hasegawa H, Yamada Y, Kamihira S: Characteristic expression of HTLV-I basic zipper factor (HBZ) transcripts in HTLV-I provirus-positive cells. Retrovirology 2008, 5:34.

143. Arnold J, Zimmerman B, Li M, Lairmore MD, Green PL: Human T-cell leukemia virus type-I antisense-encoded gene, Hbz, promotes T-lymphotropic proliferation. Blood 2008, 112:3788-3797.

144. Halin M, Doucere E, Clerc I, Journo C, Ko NL, Landry S, Murphy EL, Gessain A, Lemoiass N, Mennis JM, Barbeau B, Mahieux R: Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription. J Virol 2009, 83:2427-2438.

145. Bouzar AB, Willems L: How HTLV-I may subvert miRNAs for persistence and transformation. Retrovirology 2008, 5:101.

146. Pichler K, Schneider G, Grassmann R: MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-I-transformed lymphocytes. Retrovirology 2008, 5:100.

147. Yeung ML, Yasunaga J, Bennesser Y, Dusett N, Harris D, Ahmad N, Matsuoka M, Jeang KT: Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotropic virus type 1. Cancer Res 2008, 68:8976-8985.

148. Your research papers will be: available free of charge to the entire biomedical community cited in PubMed and archived on PubMed Central yours — you keep the copyright — you keep the copyright

Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
—Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

BioMedcentral

http://www.biomedcentral.com/content/6/1/117

Page 11 of 11 (page number not for citation purposes)